HLB Therapeutics Co.,Ltd.
115450
주식 순위
#18257
HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the... HLB Therapeutics Co.,Ltd. operates as a biotechnology company, focusing on the creation of pharmaceutical products for both the South Korean and international markets. A significant part of its research and development initiatives includes GBT-201, a compound utilizing Thymosin beta designed to treat various eye ailments such as dry eye syndrome and neurotrophic keratopathy. Additionally, the company is advancing OKN-007 as a potential therapy for glioblastoma brain tumors. Beyond its pharmaceutical endeavors, HLB Therapeutics is also involved in the wholesale distribution of vaccines and the production of electrical and electronic components like motors, pumps, and transformers. The company, which established its roots in 2000 and is based in Seongnam, South Korea, underwent a name change in December 2021, transitioning from its former identity as G-treeBNT Co., Ltd. to its current designation.
주가
$2.02
시가총액
$190.66M
변동 (1일)
7.96%
변동 (1년)
-1.16%
국가
KR
거래 HLB Therapeutics Co.,Ltd. (115450)
카테고리
Healthcare
HLB Therapeutics Co.,Ltd. (115450)의 매출
Oct 2026 기준 매출 TTM: 0
HLB Therapeutics Co.,Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
HLB Therapeutics Co.,Ltd.의 수익 기록 (2016 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2025 | $48.26M | 29.15% |
| 2024 | $37.36M | -10.01% |
| 2023 | $41.52M | 23.56% |
| 2022 | $33.60M | -8.35% |
| 2021 | $36.66M | -7.29% |
| 2020 | $39.54M | -22.56% |
| 2019 | $51.06M | 30.46% |
| 2018 | $39.14M | 143.21% |
| 2017 | $16.09M | 9.57% |
| 2016 | $14.69M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | - |
US
|
|
| $2.23B | - |
US
|
|
| $15.74B | - |
AU
|
|
| $6.02B | - |
NL
|
|
| $10.11B | - |
BE
|
